- Home
- ASAN vs RNA Comparison
ASAN vs RNA Comparison
Compare ASAN & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASAN | RNA |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 4.0B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ASAN | RNA |
|---|---|---|
| Price | $11.14 | $72.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 20 |
| Target Price | $16.58 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 3.6M | 1.6M |
| Earning Date | 03-09-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $773,570,000.00 | $20,868,000.00 |
| Revenue This Year | $11.39 | $88.12 |
| Revenue Next Year | $8.48 | $18.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 9.47 | ★ 106.27 |
| 52 Week Low | $10.59 | $21.51 |
| 52 Week High | $24.50 | $72.74 |
Technical Indicators
Market Signals| Indicator | ASAN | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 32.76 | 70.21 |
| Support Level | $10.59 | $72.23 |
| Resistance Level | $12.14 | $72.74 |
| Average True Range (ATR) | 0.52 | 0.18 |
| MACD | -0.19 | -0.11 |
| Stochastic Oscillator | 18.81 | 85.14 |
Price Performance
Historical ComparisonAbout ASAN Asana Inc.
Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.